BioPharmSignal logoBioPharmSignal

Biotech News

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Oculis (OCS)OculisClinical readout

The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division.

Related news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-06-09 08:00 EST

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

OCGNOcugen2026-09-01 11:02 EST

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OKYOOKYO Pharma2026-10-06 11:00 EST

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

PRQRProQR Therapeutics2026-06-25 10:25 EST

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

BLTEBelite Bio2026-07-20 12:00 EST

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

OCGNOcugen2026-10-06 11:02 EST

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

EYPTEyePoint Pharmaceuticals2026-08-17 11:00 EST

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

OKYOOKYO Pharma2026-09-09 11:00 EST

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

EYPTEyePoint Pharmaceuticals2026-07-30 11:00 EST

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-10-07 06:00 EST

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

OCSOculis2026-10-01 06:00 EST

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

OCSOculis2026-09-30 21:32 EST

Oculis Announces Resignation of Lionel Carnot from Board of Directors

OCSOculis2026-09-17 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-08-24 08:00 EST

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Stock data

Close
8.72 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States